Navigation Links
Genomma Lab Announces Its 2010 Earnings Guidance
Date:12/11/2009

MEXICO CITY, Dec. 11 /PRNewswire-FirstCall/ -- Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB) ("Genomma Lab" or "the Company") announces today its 2010 earnings guidance.

Genomma Lab expects net sales growth in the range of 42% to 45% for the full year of 2010, excluding possible acquisitions, and an EBITDA margin between 25.0% and 26.0%, from 2009 year-end results which we expect to be above our last issued guidance.

The Company's estimates are based on organic growth in base line products, the full year effect in sales of products launched or acquired during 2009, growth in international operations as well as product line extensions and new brands in existing and new categories.

Company Description

Genomma Lab Internacional, S.A.B. de C.V. is one of the fastest growing pharmaceutical and personal care products companies in Latin America. Genomma Lab develops, sells and markets a broad range of premium branded products, many of which are leaders in the categories in which they compete in terms of sales and market share. The Company has a sound business model through a unique combination of a new product development process, consumer oriented marketing, a broad retail distribution network and a low-cost, highly flexible supply chain operating model.

    Contact: Oscar Villalobos
    Tel:  +52 (55) 5081- 0000 ext. 4250
    E-mail: inversion@genommalab.com

    In New York: i-advize Corporate Communications, Inc.
    Tel: (212) 406-3695
    E-mail: genomma@i-advize.com

SOURCE Genomma Lab Internacional, S.A.B. de C.V.


'/>"/>
SOURCE Genomma Lab Internacional, S.A.B. de C.V.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Strategic Alliance Between Televisa and Genomma Lab
2. Genomma Lab Internacional Revises 2009 Earnings Guidance
3. Strategic Alliance Between Televisa and Genomma Lab
4. Genomma Lab International Announces Second Quarter 2009 Results
5. Webcast Alert: Genomma Lab Internacional, S.A.B. de C.V. Announces Second Quarter 2009 Results Conference Call
6. Genomma Lab Internacional Acquires Brands Flor de Naranja Sanborns(MR), Teatrical and Henna Egipcia From Grupo Sanborns
7. Genomma Lab Internacional Announces First Quarter 2009 Results
8. Genomma Lab Acquires the Mexican Company Medicinas y Medicamentos Nacionales
9. Genomma Lab Internacional Announces Fourth Quarter and Full Year 2008 Results
10. Webcast Alert: Genomma Lab Announces Fourth Quarter 2008 Earnings Webcast
11. Genomma Lab Announces Updated Fourth Quarter 2008 Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... , ... June 25, 2016 , ... First Choice ... States, named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm ... Medical Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set ... drug or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, ... traumatic event. , Trauma sufferers tend to feel a range of emotions, from depression, ...
(Date:6/24/2016)... ... 2016 , ... The Pulmonary Hypertension Association (PHA) learned during ... two significant new grants to support its work to advance research and patient ... recognizing patients, medical professionals and scientists for their work in fighting pulmonary hypertension ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):
(Date:6/26/2016)... 2016 One of Australia,s successful ... of a new biotechnology company, Noxopharm Limited [ABN 50 608 966 ... and to list on the ASX. Noxopharm is a ... enter a Phase 1 clinical study later this year. ... of the biggest problems facing cancer patients - the ability of ...
(Date:6/26/2016)... 2016 Jazz Pharmaceuticals plc (Nasdaq: ... Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), ... Inc. ("Celator"; Nasdaq: CPXX ) expired effective ... As previously announced on May 31, 2016, ... agreement under which Jazz Pharmaceuticals has commenced a tender ...
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( www.vmsrehabsystemsinc.com ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
Breaking Medicine Technology: